New data at EAN show Roche´s OCREVUSTM (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis
(WorldNews Switzerland)

Basel, 23 June 2017 New data at EAN show Roche`s OCREVUSTM (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary progressive multiple sclerosis OCREVUS increased the number of patients with relapsing MS (RMS) and primary progressive MS (PPMS) who maintained No Evidence of Progression or Active Disease (NEPAD) versus Rebif (interferon beta-1a) in RMS and placebo in PPMS OCREVUS significantly reduced the risk of RMS and PPMS patients requiring mobility aids versus comparators In PPMS patients, OCREVUS reduced the risk of more severe forms of disability progression versus placebo Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new post-hoc...